Clinical Trials

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Genitourinary

Metastatic Urothelial Cancer

NCT06727565 2026-03-02

VELOCITY-HNSCC

100 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06759649 2026-02-27

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Phase 1 Recruiting

200 enrolled

Tumor-Agnostic

Neoplasms

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

1,021 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

182 enrolled

Solid Tumor

NCT05007782 2025-12-29

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase 1 Recruiting

416 enrolled

Phase 2 Active not recruiting

Advanced Solid Tumor

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

227 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05676931 2025-10-02

EDGE-Lung

400 enrolled

Advanced Non-Small Cell Lung Cancer

NCT04772989 2025-08-28

ARC-12

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

94 enrolled

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT04262856 2025-08-26

ARC-7

Phase 2 Completed

151 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

173 enrolled

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05177770 2025-05-08

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

16 enrolled 10 charts

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03628677 2025-02-04

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

75 enrolled

Solid Tumor, Unspecified, Adult

NCT03846310 2024-12-09

ARC-4

77 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

18 enrolled

Advanced Solid Tumors

NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Phase 1 Terminated

13 enrolled 18 charts

Advanced Solid Tumors

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

48 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Phase 2 Recruiting

116 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05909436 2023-06-18

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Phase 1/2 Recruiting

107 enrolled

Solid Tumor

NCT03713905 2023-04-10

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

293 enrolled